Munich, Germany / Parsippany, New Jersey – June 1, 2010 – Definiens, the number one Enterprise Image Intelligence® company, will present its image analysis software for use in clinical trials and translational research at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from June 4th to 8th. Definiens software enables personalized medicine by providing oncology researchers and drug developers with deeper insights into the underlying biology of cancer from the analysis of digital pathology and non-invasive medical images.
Definiens digital pathology image analysis software allows pathologists to accurately identify, quantify and interpret biomarkers and cellular morphology in tissue samples on a cell-by-cell basis. With Definiens Tissue Studio™ researchers have the ability to make earlier, more informed drug prioritization decisions by validating drug-target interaction as well as the measurement of surrogate biomarkers for toxicity. Additionally, Definiens Tissue Studio™ provides automated biomarker and morphological analysis for translational research in retrospective or prospective settings.
Definiens radiology software supports the volumetric analysis of lesions and organs over time. A recent study conducted with Merck & Co. demonstrated that volumetric insight, gained with Definiens software, can provide earlier indications of a candidate compound’s efficacy, potentially shortening clinical trials and providing substantial cost savings.
ASCO meeting attendees who would like to learn more about how Definiens software supports personalized medicine and translational research are invited to visit booth 13140.
Definiens in Digital Pathology and Medical Imaging
Definiens supports biopharmaceutical companies, clinical service organizations, and academic research institutions by automating image analysis on an enterprise level, from drug discovery to diagnostics. The company’s image analysis software enables the interpretation of vast numbers of digital images accurately and consistently. Definiens image analysis software for digital pathology and non-invasive medical images reveals biologically relevant insights for the advancement of translational research and personalized medicine. More information on Definiens’ digital pathology software is available at www.tissuestudio.com. For further information on Definiens radiology software, please visit www.definiens.com/lymphexpert.
About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Medical, Life and Earth Sciences markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at: http://www.definiens.com.
Definiens, Definiens Cognition Network Technology, Definiens Cellenger, Definiens LymphExpert, Definiens Tissue Studio, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.
Press Contacts
Definiens AG
Eva Tietz
Manager Corporate Communications
etietz@definiens.com
Ricochet Public Relations
Garry Clark
Phone: +1 (212) 679-3300 x114
gclark@ricochetpr.com
